Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?

Remdesivir is an antiviral that inhibits RNA-dependent RNA polymerases of coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a cornerstone of therapy for hospitalized patients with coronavirus disease 2019 (COVID-19), especially those worsening from a respir...

Descripción completa

Detalles Bibliográficos
Autores principales: Maheshwari, Mani, Athiraman, Hemanthkumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675592/
https://www.ncbi.nlm.nih.gov/pubmed/34956798
http://dx.doi.org/10.7759/cureus.19919
_version_ 1784615901011640320
author Maheshwari, Mani
Athiraman, Hemanthkumar
author_facet Maheshwari, Mani
Athiraman, Hemanthkumar
author_sort Maheshwari, Mani
collection PubMed
description Remdesivir is an antiviral that inhibits RNA-dependent RNA polymerases of coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a cornerstone of therapy for hospitalized patients with coronavirus disease 2019 (COVID-19), especially those worsening from a respiratory standpoint despite being started on antibiotics, dexamethasone, zinc, and vitamin C. This is a case report describing two COVID-19-positive patients with bradycardia after starting remdesivir. Once remdesivir was discontinued, one patient corrected to normal sinus rhythm, and the other continued with persistent bradycardia.
format Online
Article
Text
id pubmed-8675592
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-86755922021-12-23 Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent? Maheshwari, Mani Athiraman, Hemanthkumar Cureus Cardiology Remdesivir is an antiviral that inhibits RNA-dependent RNA polymerases of coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a cornerstone of therapy for hospitalized patients with coronavirus disease 2019 (COVID-19), especially those worsening from a respiratory standpoint despite being started on antibiotics, dexamethasone, zinc, and vitamin C. This is a case report describing two COVID-19-positive patients with bradycardia after starting remdesivir. Once remdesivir was discontinued, one patient corrected to normal sinus rhythm, and the other continued with persistent bradycardia. Cureus 2021-11-26 /pmc/articles/PMC8675592/ /pubmed/34956798 http://dx.doi.org/10.7759/cureus.19919 Text en Copyright © 2021, Maheshwari et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Maheshwari, Mani
Athiraman, Hemanthkumar
Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?
title Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?
title_full Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?
title_fullStr Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?
title_full_unstemmed Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?
title_short Bradycardia Related to Remdesivir During COVID-19: Persistent or Permanent?
title_sort bradycardia related to remdesivir during covid-19: persistent or permanent?
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675592/
https://www.ncbi.nlm.nih.gov/pubmed/34956798
http://dx.doi.org/10.7759/cureus.19919
work_keys_str_mv AT maheshwarimani bradycardiarelatedtoremdesivirduringcovid19persistentorpermanent
AT athiramanhemanthkumar bradycardiarelatedtoremdesivirduringcovid19persistentorpermanent

Ejemplares similares